The ultimate goal of this research is to develop a diagnostic kit which will permit easy and rapid identification of ovarian amylase. This amylase isozyme appears to be a good indicator for ovarian cancer. In addition monoclonal antibodies will be produced which will enable reliable detection of the amounts of salivary, pancreatic, and ovarian amylases in patient specimens. It is anticipated that it will be possible to generate monoclonals which will detect specific isoelectric variants of each isozyme. During Phase I monoclonal antibodies specific for each isoenzyme will be generated. They will form the basis for kit development and clinical testing during Phase II. Such a kit permiting direct evaluation of amylase isozyme levels should prove superior to current methodologies which are either more time consuming or which rely on inhibitors for distinguishing isozymes. At present activity measurements can not distinguish ovarian from salivary isozymes. (2)
Thesaurus Terms: carbohydrases, amylase, diagnosis, diagnostic tests, design, development and evaluation of diagnostic tests, enzymes, isoenzymes, immunological preparations, monoclonal antibodies, immunological tests and immunoassay, enzyme-linked immunosorbent assay (elisa), neoplasms diagnosis, immunodiagnosis of neoplasms, neoplasms of reproductive system female, ovary neoplasms acids-bases, isoelectric point, biological preparations and standardization, natural products production by genetic manipulation, cell hybrids, hybridomas, diagnostic tests, early diagnosis, immunology, antibody specificity, neoplasms characteristics, proteins of neoplasms, oral-pharyngeal, saliva, pancreas, pancreatic enzymes, reproductive system female, ovary human, tissues, fluids etc. from non-related sources outside immediate project, mammals, rodents, myomorpha, mice (laboratory), tissue (cell) culture
